Pharmaceuticals, Biotechnology & Life Sciences

Insider buying rises at Agomab Theraputics – director David R. Epstein tops 15,000 shares, signaling confidence amid volatile market swings.

Insider trades spike after BioLife’s merger with Repligen—Goswami Joydeep sells 53k shares, CFOs buy, and investors receive cash plus Repligen stock.

CEO Tor Helen’s $18.41 per‑share buy at Halozyme confirms strong confidence in the company’s pipeline and bullish market outlook, offering investors a bullish insider signal.

Adaptive Biotechnologies insider trades: President Julie Rubinstein buys $12.14 and sells $27‑$31 on Oct 6, 2026—net outflow 2,852 shares but steady 400k‑share stake, showing disciplined plan‑based liquidity management.

ADAR1 Capital boosts its 17% stake in InMed with a steady, low‑price buy‑the‑dip strategy—signaling confidence in the company’s cannabinoid pipeline and potential future upside for investors.

Insider James Kasinger’s sharp buy‑sell‑buy moves on CRISPR Therapeutics show long‑term confidence, hinting at upside if the gene‑editing pipeline hits milestones.

Relay Therapeutics insider selling by CEO Sanjiv Patel signals a steady 10b5‑1 exit strategy amid a high‑growth biotech, urging investors to watch clinical milestones and market moves.

Analyze Martine Rothblatt’s latest United Therapeutics insider trades – see how 10b5‑1 sales and trust holdings reveal a balanced liquidity strategy.

Repligen insider Robb’s new RSU grant signals long‑term confidence in the company’s BioLife acquisition and bioprocessing strategy, hinting at potential upside for investors.

Insider buying spurs hope for Alaunos Therapeutics as key investors buy at steep discounts, hinting at a potential rebound if clinical milestones are met.